Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer
NCT07647653
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
Olaparib+Bevacizumab
DRUG:
Fluzoparib+Bevacizumab
Sponsor
Shandong University